MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Core Insights - MannKind Corporation is set to present new clinical and real-world data on Afrezza at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026) in Barcelona, Spain from March 11-14, 2026 [1][2] Group 1: Clinical Data Presentation - The data presentation will include two oral presentations: one on the efficacy of Afrezza for post-prandial glucose control across various clinical studies, and another on the INHALE-1 study focusing on pediatric patients with type 1 or type 2 diabetes [2][3] - A poster will also be presented detailing dosing and titration patterns of inhaled insulin from the INHALE-1 study in children and adolescents, where patients were initiated at an approximately 2:1 conversion from rapid-acting insulin analogs [2][3] Group 2: Pediatric Indication and FDA Review - The FDA is currently reviewing a supplemental Biologics License Application (sBLA) for Afrezza in children and adolescents aged 4-17 with type 1 or type 2 diabetes, with a target action date of May 29, 2026 [4][5] - If approved, Afrezza would be the first needle-free insulin option for pediatric patients in over 100 years [4] Group 3: Company Overview - MannKind Corporation focuses on transforming chronic disease care through innovative, patient-centric solutions, particularly in cardiometabolic and orphan lung diseases [20][21] - The company aims to develop and commercialize treatments that address serious unmet medical needs, including diabetes and pulmonary hypertension [20]